Lyell Immunopharma, Inc. (LYEL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LYEL SEC filings page.
Lyell Immunopharma, Inc. (LYEL) reported $27K in revenue over the twelve months to Jun 30, 2026, down 55.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Lyell remains a development-stage operation: research spending drives losses while its asset base and equity have steadily contracted.
By FY2025, operating cash flow of-$150.0M nearly matched free cash flow of-$150.8M , indicating little cash-flow distortion from investing or financing items. R&D spending exceeded reported revenue by over 4,000x, while capital expenditures were only$780K , so spending is primarily scientific development rather than physical expansion.
FY2025’s current ratio was 5.3x, indicating substantial reported short-term asset coverage. However, debt-to-equity rose to 0.4x from 0.2x in FY2021, so declining equity has made the same liabilities a larger claim on the company.
Operating cash outflow narrowed from
Financial Health Signals
We are recalculating Lyell Immunopharma, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Lyell Immunopharma, Inc. scores -7.16, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($211.0M) relative to total liabilities ($91.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Lyell Immunopharma, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Lyell Immunopharma, Inc. reported a net loss of $274.4M while operations used $150.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Lyell Immunopharma, Inc. generated $4K in revenue in Q2 2026. This represents a decrease of 50.0% from the same quarter a year earlier. Against the prior quarter it is up 100.0%.
Lyell Immunopharma, Inc.'s EBITDA was -$45.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.5% from the same quarter a year earlier. Against the prior quarter it is down 7.6%.
Lyell Immunopharma, Inc. reported -$44.8M in net income in Q2 2026. This represents a decrease of 4.9% from the same quarter a year earlier. Against the prior quarter it is down 85.3%.
Lyell Immunopharma, Inc. earned -$1.92 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 74.5%.
Cash & Balance Sheet
Lyell Immunopharma, Inc. recorded an outflow of $34.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 1.3% from the same quarter a year earlier. Against the prior quarter it is up 11.5%.
Lyell Immunopharma, Inc. held $73.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Lyell Immunopharma, Inc.'s ROE was -19.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 4.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.3 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Lyell Immunopharma, Inc. invested $39.5M in research and development in Q2 2026. This represents an increase of 13.4% from the same quarter a year earlier. Against the prior quarter it is up 8.0%.
Lyell Immunopharma, Inc. invested $256K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 52.4% from the same quarter a year earlier. Against the prior quarter it is up 187.6%.
Not reported for Q2 2026.
LYEL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4K-50.0% | $2K-71.4% | $6K-45.5% | $15K-55.9% | $8K-38.5% | $7K+133.3% | $11K-15.4% | $34K+36.0% |
| R&D Expenses | $39.5M+13.4% | $36.6M-15.8% | $52.2M+7.3% | $28.2M-28.7% | $34.9M-13.4% | $43.4M+0.6% | $48.7M+3.6% | $39.5M-9.9% |
| SG&A Expenses | $9.6M-2.1% | $9.6M-32.0% | $10.6M-26.9% | $10.7M-9.2% | $9.8M-20.2% | $14.0M+4.1% | $14.5M+10.3% | $11.8M-24.1% |
| Operating Income | -$47.3M-0.4% | -$44.3M+22.8% | -$127.6M+36.5% | -$37.3M+26.2% | -$47.1M+8.5% | -$57.4M-3.2% | -$201.1M-238.0% | -$50.5M+14.5% |
| EBITDA | -$45.1M-2.5% | -$41.9M+22.2% | -$125.2M+36.1% | -$34.7M+24.3% | -$44.0M+5.6% | -$53.9M-6.7% | -$196.1M-260.2% | -$45.8M+15.0% |
| Net Income | -$44.8M-4.9% | -$24.2M+53.7% | -$140.7M+26.7% | -$38.8M+12.9% | -$42.7M+6.8% | -$52.2M+14.0% | -$191.9M-262.6% | -$44.6M+12.3% |
| EPS (Basic) | -$1.92+33.6% | -$1.10+68.9% | -$7.68+46.7% | -$2.13+38.8% | -$2.89+19.5% | -$3.54-1375.0% | -$14.40-7100.0% | -$3.48-1640.0% |
| EPS (Diluted) | -$1.92 | -$1.10+68.9% | -$7.68 | -$2.13 | -$2.89 | -$3.54 | -$14.40 | -$3.48 |
| Diluted Shares (Avg) | 23M | 22M+48.3% | N/A | 18M | 15M | 15M | N/A | 13M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
LYEL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $311.2M-19.3% | $350.6M-18.4% | $340.1M-30.7% | $408.0M-34.1% | $385.5M-41.1% | $429.8M-38.1% | $490.9M-34.6% | $619.2M-22.1% |
| Current Assets | $213.5M-24.3% | $267.3M-13.5% | $260.9M-31.3% | $328.2M-27.1% | $282.2M-43.5% | $309.2M-42.1% | $379.6M-31.6% | $450.0M-23.3% |
| Cash & Equivalents | $73.0M-26.1% | $90.8M-24.6% | $60.2M-43.0% | $123.6M+23.2% | $98.8M-25.9% | $120.3M-4.2% | $105.6M-27.5% | $100.3M-65.0% |
| Short-Term Investments | $131.1M-26.3% | $163.3M-9.7% | $187.0M-29.4% | $196.0M-42.4% | $178.0M-50.2% | $180.8M-54.9% | $264.9M-33.9% | $340.2M+17.6% |
| Long-Term Investments | $23.9M+19.1% | $7.0M-76.0% | $0-100.0% | $0-100.0% | $20.1M | $28.9M | $13.0M-21.2% | $20.1M-11.5% |
| Total Liabilities | $77.3M-10.6% | $77.0M-17.5% | $91.8M-15.0% | $78.8M-10.9% | $86.5M-1.3% | $93.3M+2.4% | $108.0M+13.6% | $88.5M-9.1% |
| Current Liabilities | $39.9M+8.0% | $36.9M-10.5% | $49.4M-8.1% | $31.9M-4.9% | $36.9M+19.5% | $41.3M+27.6% | $53.8M+55.8% | $33.5M-4.4% |
| Non-Current Liabilities | $37.5M-24.5% | $40.0M-23.0% | $42.4M-21.8% | $47.0M-14.6% | $49.6M-12.6% | $52.0M-11.4% | $54.2M-10.4% | $55.0M-11.8% |
| Total Equity | $233.8M-21.8% | $273.7M-18.7% | $248.2M-35.2% | $329.1M-38.0% | $298.9M-47.2% | $336.5M-44.2% | $382.8M-41.5% | $530.7M-23.9% |
| Retained Earnings | -$1.7B-17.3% | -$1.6B-17.6% | -$1.6B-20.4% | -$1.5B-28.2% | -$1.4B-29.9% | -$1.4B-31.5% | -$1.3B-34.2% | -$1.2B-21.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LYEL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.9M+1.6% | -$38.5M+29.6% | -$32.3M+31.7% | -$28.6M+18.4% | -$34.5M+9.5% | -$54.7M-30.3% | -$47.2M-16.3% | -$35.0M+7.0% |
| Depreciation & Amortization | $2.2M-29.1% | $2.3M-32.2% | $2.4M-52.3% | $2.6M-45.2% | $3.1M-36.0% | $3.4M-31.5% | $5.0M-0.6% | $4.7M-8.3% |
| Stock-Based Compensation | $4.5M-9.4% | $4.3M-28.7% | N/A | $5.2M-31.4% | $5.0M-39.6% | $6.0M-34.2% | N/A | $7.6M-27.5% |
| Capital Expenditures | $256K+52.4% | $89K-63.8% | $304K+590.9% | $62K+5.1% | $168K-49.2% | $246K+720.0% | $44K+76.0% | $59K-69.7% |
| Free Cash Flow | -$34.2M+1.3% | -$38.6M+29.8% | -$32.6M+31.2% | -$28.6M+18.4% | -$34.6M+9.9% | -$55.0M-30.8% | -$47.3M-16.3% | -$35.1M+7.3% |
| Investing Cash Flow | $15.6M+23.5% | $17.4M-75.0% | -$31.4M-158.6% | $3.3M+74.6% | $12.6M-71.9% | $69.5M+215.8% | $53.5M+153.1% | $1.9M-98.1% |
| Financing Cash Flow | $522K+185.2% | $51.7M+5172100.0% | $222K-49.2% | $50.0M | $183K-78.8% | $1K-96.3% | $437K-42.4% | $0+100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
LYEL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1183425.0% | -2213050.0% | -2127400.0% | -248353.3% | -589250.0% | -819528.6% | -1828609.1% | -148544.1% |
| Net Margin | -1118875.0% | -1207650.0% | -2345383.3% | -258973.3% | -533550.0% | -745642.9% | -1744863.6% | -131126.5% |
| Return on Equity | -19.1%-4.9pp | -8.8%+6.7pp | -56.7%-6.6pp | -11.8%-3.4pp | -14.3%-6.2pp | -15.5%-5.4pp | -50.1%-42.1pp | -8.4%-1.1pp |
| Return on Assets | -14.4%-3.3pp | -6.9%+5.2pp | -41.4%-2.3pp | -9.5%-2.3pp | -11.1%-4.1pp | -12.1%-3.4pp | -39.1%-32.0pp | -7.2%-0.8pp |
| Current Ratio | 5.36-2.3x | 7.23-0.3x | 5.28-1.8x | 10.30-3.1x | 7.65-8.5x | 7.49-9.0x | 7.06-9.0x | 13.43-3.3x |
| Debt-to-Equity | 0.330.0x | 0.280.0x | 0.37+0.1x | 0.24+0.1x | 0.29+0.1x | 0.28+0.1x | 0.28+0.1x | 0.170.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x | 0.000.0x |
| FCF Margin | -854450.0% | -1929950.0% | -542583.3% | -190926.7% | -432825.0% | -785485.7% | -429872.7% | -103238.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. LYEL | FY2025 | $36K | -$274.4M | N/A | $211.0M | — |
| Candel Therapeutics, Inc. CADL | FY2025 | N/A | -$38.2M | N/A | $782.8M | — |
| Invivyd, Inc. IVVD | FY2025 | $53.4M | -$52.5M | -98.3% | $247.4M | 68/100 |
| Neumora Therapeutics, Inc. NMRA | FY2025 | N/A | $236.9M | N/A | $98.7M | — |
| Atea Pharmaceuticals, Inc. AVIR | FY2025 | N/A | -$158.0M | N/A | $411.5M | — |
| Allogene Therapeutics, Inc. ALLO | FY2025 | $0 | -$190.9M | N/A | $518.2M | — |
Where Lyell Immunopharma, Inc. Ranks
Frequently Asked Questions
What is Lyell Immunopharma, Inc.'s annual revenue?
Lyell Immunopharma, Inc. (LYEL) reported $36K in total revenue for fiscal year 2025. This represents a -41.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lyell Immunopharma, Inc.'s revenue growing?
Lyell Immunopharma, Inc. (LYEL) revenue declined by 41.0% year-over-year, from $61K to $36K in fiscal year 2025.
Is Lyell Immunopharma, Inc. profitable?
No, Lyell Immunopharma, Inc. (LYEL) reported a net income of -$274.4M in fiscal year 2025.
What is Lyell Immunopharma, Inc.'s EBITDA?
Lyell Immunopharma, Inc. (LYEL) had EBITDA of -$257.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lyell Immunopharma, Inc.'s return on equity (ROE)?
Lyell Immunopharma, Inc. (LYEL) has a return on equity of -110.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lyell Immunopharma, Inc.'s free cash flow?
Lyell Immunopharma, Inc. (LYEL) recorded an outflow of $150.8M in free cash flow during fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lyell Immunopharma, Inc.'s operating cash flow?
Lyell Immunopharma, Inc. (LYEL) recorded an outflow of $150.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Lyell Immunopharma, Inc.'s total assets?
Lyell Immunopharma, Inc. (LYEL) had $340.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lyell Immunopharma, Inc.'s capital expenditures?
Lyell Immunopharma, Inc. (LYEL) invested $780K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lyell Immunopharma, Inc. spend on research and development?
Lyell Immunopharma, Inc. (LYEL) invested $158.7M in research and development during fiscal year 2025.
What is Lyell Immunopharma, Inc.'s current ratio?
Lyell Immunopharma, Inc. (LYEL) had a current ratio of 5.28 as of fiscal year 2025, which is generally considered healthy.
What is Lyell Immunopharma, Inc.'s debt-to-equity ratio?
Lyell Immunopharma, Inc. (LYEL) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Lyell Immunopharma, Inc.'s return on assets (ROA)?
Lyell Immunopharma, Inc. (LYEL) had a return on assets of -80.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lyell Immunopharma, Inc.'s P/E ratio?
Lyell Immunopharma, Inc. (LYEL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $211.0M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Lyell Immunopharma, Inc.'s price-to-sales ratio?
Lyell Immunopharma, Inc. (LYEL) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $27K revenue, trailing 12 months to June 30, 2026). The market capitalization is $211.0M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Lyell Immunopharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Lyell Immunopharma, Inc. (LYEL) held $247.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $150.0M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Lyell Immunopharma, Inc.'s Altman Z-Score?
Lyell Immunopharma, Inc. (LYEL) has an Altman Z-Score of -7.16, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Lyell Immunopharma, Inc.'s Piotroski F-Score?
Lyell Immunopharma, Inc. (LYEL) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lyell Immunopharma, Inc.'s earnings high quality?
Lyell Immunopharma, Inc. (LYEL) reported a net loss of $274.4M while operations used $150.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.